Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Live updates

1. 2h ago

   Tango Reports 82% Tumor Response in Pancreatic Cancer Trial

   Tango Therapeutics reported an 82% objective response rate for its experimental combination therapy targeting advanced pancreatic cancer at the ESMO 2026 congress. The trial evaluated vopimetostat combined with daraxonrasib in previously treated patients carrying MTAP deletions and RAS mutations. Although the response rate dipped from an earlier 92% figure in a smaller cohort, the updated data included 22 evaluable patients. Tango announced plans to advance the combination into a global Phase III trial as a first-line treatment in the first half of 2027.

   Why it matters

   Pancreatic cancer remains a difficult disease to treat with single-agent therapies, leading developers to test combination approaches. The trial builds on prior success achieved by Revolution Medicines with its Rasonque drug. Analysts and investors are closely monitoring how targeted drug combinations perform against difficult mutations like MTAP deletion in metastatic pancreatic ductal adenocarcinoma.

   What is confirmed

   • Tango Therapeutics reported an 82% objective response rate for vopimetostat combined with daraxonrasib in previously treated pancreatic cancer patients at ESMO 2026.
   • The updated Phase 1/2 trial results included 22 evaluable patients with MTAP deletion and RAS mutation.
   • Tango plans to begin a global Phase III trial in the first half of 2027 evaluating the combination as a first-line treatment for metastatic pancreatic ductal adenocarcinoma.
   • Tango stock fell despite the positive cancer trial data presented at ESMO 2026.

   Still unconfirmed

   • Tango Therapeutics stock fell because the response rate dropped from an earlier 92% reading reported in June among a smaller group of patients.

   What to watch next

   • Initiation of the global Phase III trial in the first half of 2027.
   • Further maturity of progression-free survival data as the trial progresses.
   Sources used for this update (14)

   1. STAT — Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer
   2. Endpoints News — Tango combo clears Rasonque bar, Takeda’s Innovent bet gets early returns, plus more from #ESMO26
   3. Yahoo Finance — Tango Therapeutics stock falls despite positive cancer trial data
   4. Investor's Business Daily — How Tango Improved On Revolution's 'Unprecedented' Results
   5. Targeted Oncology — Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
   6. STAT — Tango builds on Revolution Medicines’ pancreatic cancer success
   7. BioSpace — ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3
   8. trial.medpath.com — Tango, Revolution Medicines combo yields 82% tumor response ...
   9. evagene.com — Tango Therapeutics reports 82% tumour response rate for ...
   10. www.marketbeat.com — Tango Therapeutics Targets 2027 Phase III Trial After 82% ...
   11. www.statnews.com — Tango Therapeutics reports pancreatic cancer results| STAT
   12. www.talk.bio — Tango’s pancreatic cancer combo shows 82% response rate
   confidence 95%